Safety and tolerability of subcutaneous trastuzumab at home administration, results of the phase IIIb open-label BELIS study in HER2-positive early breast cancer

被引：0
|
作者：
Hannelore Denys
Corina L. Martinez-Mena
Marc T. Martens
Randal G. D’Hondt
Marie-Pascale L. Graas
Ella Evron
Georgeta Fried
Noa E. Ben-Baruch
Christof Vulsteke
Mona M. Van Steenberghe
机构：
[1] UZ Gent,Integrated Cancer Center Ghent
[2] CHU St Pierre,Center for Oncological Research (CORE)
[3] AZ Turnhout,undefined
[4] AZ Damiaan,undefined
[5] CHC - Clinique Saint-Joseph,undefined
[6] Assaf Harofeh Medical Center,undefined
[7] Rambam Medical Center,undefined
[8] Kaplan Medical Center,undefined
[9] AZ Maria Middelares,undefined
[10] Antwerp University,undefined
[11] Roche nv/sa,undefined
来源：
Breast Cancer Research and Treatment | 2020年 / 181卷
关键词：
Safety; Tolerability; Subcutaneous trastuzumab; HER2-positive early breast cancer; At home administration;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：97 / 105
页数：8
相关论文
共 50 条
  • [41] Interim results of a prospective, open-label, multicentre phase II trial of the efficacy and safety of vinorelbine (N) and trastuzumab (H) in patients with HER2-positive metastatic breast cancer (MBC).
    De Wit, M
    Harbeck, N
    Thomssen, C
    Becker, K
    Psonka, A
    Hoffmann, R
    Villena, C
    Schutte, M
    Hossfeld, DK
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 84S - 84S
  • [42] Subcutaneous trastuzumab: development of a new formulation for treatment of HER2-positive early breast cancer
    Hamizi, Salima
    Freyer, Gilles
    Bakrin, Naoual
    Henin, Emilie
    Mohtaram, Amina
    Le Saux, Olivia
    Falandry, Claire
    ONCOTARGETS AND THERAPY, 2013, 6 : 89 - 94
  • [43] Subcutaneous administration of the fixed-dose combination of trastuzumab and pertuzumab in combination with chemotherapy in HER2-positive early breast cancer: Primary analysis of the phase III, multicenter, randomized, open-label, two-arm FeDeriCa study
    Tan, Antoinette R.
    Im, Seock-Ah
    Mattar, Andre
    Colomer, Ramon
    Stroyakovskii, Daniil
    Nowecki, Zbigniew
    De laurentiis, Michelino
    Pierga, Jean-Yves
    Jung, Kyung Hae
    Schem, Christian
    Heeson, Sarah
    Shivhare, Mahesh
    Kirschbrown, Whitney P.
    Restuccia, Eleonora
    Crnjevic, Tanja Badovinac
    Jackisch, Christian
    CANCER RESEARCH, 2020, 80 (04)
  • [44] Pertuzumab retreatment for HER2-positive advanced breast cancer: A randomized, open-label phase III study (PRECIOUS)
    Yamamoto, Yutaka
    Iwata, Hiroji
    Taira, Naruto
    Masuda, Norikazu
    Takahashi, Masato
    Yoshinami, Tetsuhiro
    Ueno, Takayuki
    Toyama, Tatsuya
    Yamanaka, Takashi
    Takano, Toshimi
    Kashiwaba, Masahiro
    Tsugawa, Koichiro
    Hasegawa, Yoshie
    Tamura, Kenji
    Tada, Hiroshi
    Hara, Fumikata
    Fujisawa, Tomomi
    Niikura, Naoki
    Saji, Shigehira
    Morita, Satoshi
    Toi, Masakazu
    Ohno, Shinji
    CANCER SCIENCE, 2022, 113 (09) : 3169 - 3179
  • [45] Patients' preference of trastuzumab administration (subcutaneous versus intravenous) in HER2-positive metastatic breast cancer: Results of the randomised MetaspHer study
    Pivot, X.
    Spano, J. P.
    Espie, M.
    Cottu, P.
    Jouannaud, C.
    Pottier, V.
    Moreau, L.
    Extra, J. M.
    Lortholary, A.
    Rivera, P.
    Spaeth, D.
    Attar-Rabia, H.
    Benkanoun, C.
    Dima-Martinez, L.
    Esposito, N.
    Gligorov, J.
    EUROPEAN JOURNAL OF CANCER, 2017, 82 : 230 - 236
  • [46] A time and motion study of subcutaneous versus intravenous trastuzumab in patients with HER2-positive early breast cancer
    De Cock, Erwin
    Pivot, Xavier
    Hauser, Nik
    Verma, Sunil
    Kritikou, Persefoni
    Millar, Douglas
    Knoop, Ann
    CANCER MEDICINE, 2016, 5 (03): : 389 - 397
  • [47] Subcutaneous versus intravenous administration of (neo)adjuvant trastuzumab in patients with HER2-positive, clinical stage I-III breast cancer (HannaH study): a phase 3, open-label, multicentre, randomised trial
    Ismael, Gustavo
    Hegg, Roberto
    Muehlbauer, Susanne
    Heinzmann, Dominik
    Lum, Bert
    Kim, Sung-Bae
    Pienkowski, Tadeusz
    Lichinitser, Mikhail
    Semiglazov, Vladimir
    Melichar, Bohuslav
    Jackisch, Christian
    LANCET ONCOLOGY, 2012, 13 (09): : 869 - 878
  • [48] Pyrotinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer : a multicenter, open-label, phase 2 trial
    Cao, F.
    Ma, Z.
    Hu, G.
    Zhu, X.
    Li, S.
    Chen, S.
    Chen, B.
    Li, Z.
    Wu, W.
    Ji, X.
    Shu, J.
    Tao, D.
    Hu, X.
    Zheng, M.
    Wang, O.
    Feng, Q.
    Hao, J.
    Li, X.
    BREAST, 2023, 68 : S16 - S16
  • [49] Final results of the global and Asia cohorts of KAMILLA, a phase IIIB safety trial of trastuzumab emtansine in patients with HER2-positive advanced breast cancer
    Wuerstlein, R.
    Ellis, P.
    Montemurro, F.
    Anton Torres, A.
    Delaloge, S.
    Zhang, Q.
    Wang, X.
    Wang, S.
    Shao, Z.
    Li, H.
    Rachman, A.
    Vongsaisuwon, M.
    Liu, H.
    Fear, S.
    Pena-Murillo, C.
    Barrios, C.
    ESMO OPEN, 2022, 7 (05)
  • [50] Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial
    Hurvitz, Sara A.
    Hegg, Roberto
    Chung, Wei-Pang
    Im, Seock-Ah
    Jacot, William
    Ganju, Vinod
    Chiu, Joanne Wing Yan
    Xu, Binghe
    Hamilton, Erika
    Madhusudan, Srinivasan
    Iwata, Hiroji
    Altintas, Sevilay
    Henning, Jan-Willem
    Curigliano, Giuseppe
    Perez-Garcia, Jose Manuel
    Kim, Sung-Bae
    Petry, Vanessa
    Huang, Chiun-Sheng
    Li, Wei
    Frenel, Jean-Sebastien
    Antolin, Silvia
    Yeo, Winnie
    Bianchini, Giampaolo
    Loi, Sherene
    Tsurutani, Junji
    Egorov, Anton
    Liu, Yali
    Cathcart, Jillian
    Ashfaque, Shahid
    Cortes, Javier
    LANCET, 2023, 401 (10371): : 105 - 117
12345